Flavokawain A: A Natural MAO‐A Inhibitor With Therapeutic Promise for Depression
Chemistry & Biodiversity · 2026
DOI: 10.1002/cbdv.202501920 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemistry & Biodiversity, 2026. Verfasst von Vaishnavi Pawa und 11 weiteren Autor:innen. Beteiligte Einrichtung: R.C. Patel Institute of Pharmaceutical Education & Research, Near Karwand Naka, Shirpur, Dhule, Maharashtra, India. Hauptthemen laut MEDLINE: Monoamine Oxidase Inhibitors, Monoamine Oxidase, Depression, Antidepressive Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Nvidia.
Themen: Depression
Abstract (Originalsprache)
Flavokawain A, a naturally occurring chalcone derived from Piper methysticum , has been explored for its neurotherapeutic potential. This study investigates the inhibitory activity of flavokawain A against both MAO‐A and MAO‐B isoforms using a comprehensive approach that integrates in vitro enzyme assays with in silico modelling techniques. Flavokawain A exhibited potent and selective inhibition of MAO‐A, with an IC 50 value of 0.077 µM and a moderate selectivity index of 4.84, as compared to the clinically used reversible MAO‐A inhibitor toloxatone. Blood–brain barrier permeability, assessed via parallel artificial membrane permeability assay, confirmed flavokawain A's central nervous system (CNS) drug‐likeness. Molecular docking and dynamics simulations revealed strong and stable binding of flavokawain A within the MAO‐A active site, supported by key hydrogen bonds and hydrophobic interactions, particularly involving Tyr444 and Lys305. Post‐dynamic analyses, including principal component analysis (PCA), dynamic cross‐correlation matrix (DCCM), and free energy landscape (FEL) mapping, indicated greater conformational adaptability and domain cooperativity in MAO‐A compared to MAO‐B. Quantum chemical (density functional theory) analysis further validated the reactivity and binding potential of flavokawain A. Collectively, these findings position flavokawain A as a promising natural, CNS‐permeant lead compound with selective MAO‐A inhibitory activity, supporting its further development for the treatment of depression and related neuropsychiatric disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- R.C. Patel Institute of Pharmaceutical Education & Research, Near Karwand Naka, Shirpur, Dhule, Maharashtra, India.
- Department of Pharmacy, Research Institute of Life Pharmaceutical Sciences, Sunchon National University, Suncheon, Republic of Korea.
- Department of Pharmaceutical Chemistry, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, Kochi, India.
ORCID-Profile: Harun M Patel
Förderung
- Nvidia
Zitieren
APA
Pawa, V., Shimpi, A., Oh, J. M., Kadam, V., Patil, B., Gawli, C., Jagtap, V., Mathew, B., Sudevan, S., Ansari, I., Kim, H., & Patel, H. M. (2026). Flavokawain A: A Natural MAO‐A Inhibitor With Therapeutic Promise for Depression. Chemistry & Biodiversity. https://doi.org/10.1002/cbdv.202501920
Vancouver
Pawa V, Shimpi A, Oh JM, Kadam V, Patil B, Gawli C, et al. Flavokawain A: A Natural MAO‐A Inhibitor With Therapeutic Promise for Depression. Chemistry & Biodiversity. 2026. doi:10.1002/cbdv.202501920
BibTeX
@article{Pawa2026,
author = {Pawa, Vaishnavi and Shimpi, Amit and Oh, Jong Min and Kadam, Vaibhav and Patil, Bhatu and Gawli, Chandrakant and Jagtap, Vilas and Mathew, Bijo and Sudevan, Sachithra and Ansari, Iqrar and Kim, Hoon and Patel, Harun M},
title = {Flavokawain A: A Natural MAO‐A Inhibitor With Therapeutic Promise for Depression},
journal = {Chemistry & Biodiversity},
year = {2026},
doi = {10.1002/cbdv.202501920}
}
EUVIMED